DACLATASVIR dihydrochloride (DCV), eq. 60mg base, break.tab.


Valid Article - Pangenotypic direct-acting antiviral combinations
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list


Add Kit To Wishlist



Therapeutic Action

Inhibitor of the multifunctional protein NS5A


Chronic hepatitis C virus (HCV), in combination with other antiviral medicines

Instructions for use

To be used in combination with sofosbuvir, with or without ribavirin:

  • In children, daclatasvir 60 mg is used in combination with sofosbuvir 200 mg.
  • In adults, a fixed-dose combination (FDC) of daclatasvir 60mg / sofosbuvir 400mg is available.


Below 25ºC